heterocyclic-imidazoline compounds have been prepared and evaluated in vitro as imidazoline sites (I1 and I2) and alpha-adrenergic (alpha1 and alpha2) receptor ligands. Their pKi values indicate that linkage of the imidazoline moiety at the 2-position with an aromatic substituent dramatically decreases alpha-adrenergic affinity. I1 sites are more accessible by phenyl imidazolines substituted by a methyl or a methoxy
tetrazoles, triazoles, and imidazolines. The magnetic silica sphere grafted sulfonic acid (MSS-SO3H) is suitable for the synthesis of 1,2,3-triazole via the cycloaddition of nitroalkene with NaN3, whereas the zinc-modified silica sphere catalyst (MSS-SO3Zn) is more suitable for the synthesis of tetrazoles. The MSS-SO3Zn catalyst also works well for the synthesis of 2-substituted imidazoline via the condensation
Fragmentation of Trifluoromethylated Alkenes and Acetylenes by <i>N</i>,<i>N</i>-Binucleophiles. Synthesis of Imidazolines or Imidazolidines (Oxazolidines) Controlled by Substituent
作者:Valentine G. Nenajdenko、Vasiliy M. Muzalevskiy、Aleksey V. Shastin、Elizabeth S. Balenkova、Evgeniy V. Kondrashov、Igor A. Ushakov、Alexander Yu. Rulev
DOI:10.1021/jo101107t
日期:2010.8.20
The reaction of β-halogeno-β-polyfluoromethylstyrenes with N,N- or N,O-binucleophiles leads to unexpected fragmentation products (imidazolines) or to heterocyclization giving CF3-substituted imidazolidines (N,N-) and oxazolidines (N,O-) depending on aryl substituent. The scope and the reaction mechanism are discussed.
The Chan–Evans–Lam <i>N</i>-Arylation of 2-Imidazolines
作者:Dmitry Dar’in、Mikhail Krasavin
DOI:10.1021/acs.joc.6b02404
日期:2016.12.16
N-Arylation of 2-imidazolines with arylboronic acids promoted by copper(II) acetate in DMSO provides an attractive alternative to the earlier reported transition metal-catalyzed approaches employing (hetero)aryl halides as it taps into the vast reagent space of commercially available boronic acids and proceeds at ambient temperature. Many of the resulting compounds are distinctly lead-like, thus positioning
Imidazoisoindole Neuropeptide S Receptor Antagonists
申请人:Manley Peter J.
公开号:US20110212941A1
公开(公告)日:2011-09-01
The present invention is directed to imidazoisoindole compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.